Grand Pharmaceutical Group (HKSE:00512) EBIT per Share : HK$0.72 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group EBIT per Share?

Grand Pharmaceutical Group's EBIT per Share for the six months ended in Dec. 2023 was HK$0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.72.

During the past 12 months, the average EBIT per Share Growth Rate of Grand Pharmaceutical Group was 6.30% per year. During the past 3 years, the average EBIT per Share Growth Rate was 16.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 19.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 24.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Grand Pharmaceutical Group's EBIT per Share or its related term are showing as below:

HKSE:00512' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -9.4 Med: 25.75 Max: 79.3
Current: 16.2

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Grand Pharmaceutical Group was 79.30% per year. The lowest was -9.40% per year. And the median was 25.75% per year.

HKSE:00512's 3-Year EBIT Growth Rate is ranked better than
62.34% of 863 companies
in the Drug Manufacturers industry
Industry Median: 7.3 vs HKSE:00512: 16.20

Grand Pharmaceutical Group's EBIT for the six months ended in Dec. 2023 was HK$1,110 Mil.

Grand Pharmaceutical Group EBIT per Share Historical Data

The historical data trend for Grand Pharmaceutical Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group EBIT per Share Chart

Grand Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.45

0.64

0.81

0.75

0.73

Grand Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.41	0.28	0.47	0.41	0.32

Grand Pharmaceutical Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Grand Pharmaceutical Group's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	2549.342	/	3507.754
=	0.73

Grand Pharmaceutical Group's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1110.412	/	3501.810
=	0.32

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.72

Grand Pharmaceutical Group (HKSE:00512) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Grand Pharmaceutical Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Grand Pharmaceutical Group (HKSE:00512) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » EBIT per Share

Traded in Other Exchanges

MX6A:Germany

Address

99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG

Website

http://www.chinagrandpharm.com

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Executives

Shang Hai Yuan Da Chan Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Hu Kaijun	2201 Interest of corporation controlled by you
East Ocean Capital (hong Kong) Company Limited	2101 Beneficial owner
Lion River I N.v.	2201 Interest of corporation controlled by you
Li Zhenfu	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.	2201 Interest of corporation controlled by you
Assicurazioni Generali Spa	2201 Interest of corporation controlled by you
Citic Group Corporation	2201 Interest of corporation controlled by you
Citic Limited	2201 Interest of corporation controlled by you
China Citic Bank Corporation Limited	2201 Interest of corporation controlled by you
Cncb (hong Kong) Investment Limited	2106 Person having a security interest in shares
Grand (hongkong) International Investments Holdings Limited
Chau Tung
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si
Outwit Investments Limited

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines